Celularity Inc CELU
Celularity Inc (Nasdaq: CELU) is a drug developer. Its lead program, cenplacel-L, is in Phase 2 for diabetic foot ulcers (and age-related frailty under evaluation).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| cenplacel-L | diabetic foot ulcers | cell therapy | Phase 2 |
| cenplacel-L | age-related frailty | cell therapy | Pre-clinical |
| CYNK-001 | immune function and clearance of senescent cells | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.